Spruce Biosciences Prices Public Offering at $50 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy SPRB?
Source: Yahoo Finance
- Offering Size: Spruce Biosciences announced a public offering of 1,150,000 shares at $50.00 per share, expecting gross proceeds of $60 million, indicating strong fundraising capability in the biopharmaceutical sector.
- Pre-Funded Warrant Arrangement: The offering includes pre-funded warrants for 50,000 shares at a purchase price of $49.99 per share for a specific investor, reflecting the company's flexible financing strategy to meet investor demand.
- Underwriter Team: The offering is managed by Leerink Partners, Guggenheim Securities, and Oppenheimer & Co., demonstrating market confidence and support for Spruce Biosciences.
- Registration Statement Validity: The offering is based on a shelf registration statement filed on October 29, 2025, indicating the company's commitment to compliance and transparency, which helps enhance investor trust.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SPRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SPRB
Wall Street analysts forecast SPRB stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 70.300
Low
160.00
Averages
230.50
High
283.00
Current: 70.300
Low
160.00
Averages
230.50
High
283.00
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Spruce Biosciences Prices Public Offering at $50 per Share
- Public Offering Pricing: Spruce Biosciences has priced its public offering of 1.15 million common stock shares at $50.00 each, expecting total gross proceeds of $60 million, indicating the company's ability to raise capital in the market.
- Pre-Funded Warrants: The company is also offering pre-funded warrants for 50,000 shares at $49.99 each to a specific investor, a strategy aimed at attracting investment and enhancing liquidity.
- Additional Share Option: Spruce Biosciences has granted underwriters a 30-day option to purchase up to 180,000 additional shares, which could further increase the total financing and meet market demand.
- Stock Price Reaction: Following the public offering announcement, Spruce Biosciences' stock price fell 13.44% in after-hours trading to $60.50, reflecting market caution regarding the offering.
See More
Spruce Biosciences Prices Public Offering at $50 per Share
- Offering Size: Spruce Biosciences announced a public offering of 1,150,000 shares at $50.00 per share, expecting gross proceeds of $60 million, reflecting the company's strong fundraising capability and market confidence in the biopharmaceutical sector.
- Pre-Funded Warrant Arrangement: The offering includes pre-funded warrants for 50,000 shares at a purchase price of $49.99 per share for a specific investor, indicating the company's flexible financing strategy to attract investment.
- Underwriter Lineup: The offering is managed by Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. as joint book-running managers, showcasing the company's strong backing and professionalism in capital markets.
- Registration Statement Validity: The offering is conducted under a shelf registration statement on Form S-3 filed on October 29, 2025, and declared effective by the SEC on November 26, 2025, ensuring compliance and transparency in the fundraising process.
See More
Spruce Biosciences Prices Public Offering at $50 per Share
- Offering Size: Spruce Biosciences announced a public offering of 1,150,000 shares at $50.00 per share, expecting gross proceeds of $60 million, indicating strong fundraising capability in the biopharmaceutical sector.
- Pre-Funded Warrant Arrangement: The offering includes pre-funded warrants for 50,000 shares at a purchase price of $49.99 per share for a specific investor, reflecting the company's flexible financing strategy to meet investor demand.
- Underwriter Team: The offering is managed by Leerink Partners, Guggenheim Securities, and Oppenheimer & Co., demonstrating market confidence and support for Spruce Biosciences.
- Registration Statement Validity: The offering is based on a shelf registration statement filed on October 29, 2025, indicating the company's commitment to compliance and transparency, which helps enhance investor trust.
See More
SPRUCE BIOSCIENCES, INC ANNOUNCES PUBLIC OFFERING OF 1,150,000 SHARES PRICED AT $50.00 EACH
Company Announcement: Spruce Biosciences, Inc. has announced a public offering of 1,150,000 shares.
Share Price: The shares are being offered at a price of $50.00 per share.
See More
SPRUCE BIOSCIENCES REVEALS PRICING FOR PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS
Public Offering Announcement: Spruce Biosciences has announced the pricing of its public offering of common stock.
Pre-Funded Warrants: The offering also includes pre-funded warrants, allowing investors to purchase shares at a reduced price.
See More
Spruce Biosciences Launches Public Offering
- Public Offering Initiation: Spruce Biosciences announced late Monday that it has commenced an underwritten public offering, although the specific amount to be raised has not been disclosed, indicating the company's intent to enhance financial flexibility through capital markets.
- Market Reaction Anticipation: This offering may attract investor interest, particularly in the biotech sector, as the potential use of funds could include research and development and market expansion, thereby enhancing the company's long-term growth prospects.
- Strategic Financing Plan: The implementation of the public offering will provide the necessary funding support for the company to advance its product development and clinical trials, especially in the currently competitive biopharmaceutical market.
- Investor Confidence Challenge: While market reactions to biotech offerings can vary, Spruce Biosciences' action may influence its stock performance, prompting investors to monitor subsequent market feedback and the company's financial health.
See More
Spruce Biosciences Prices Public Offering at $50 per Share
- Public Offering Pricing: Spruce Biosciences has priced its public offering of 1.15 million common stock shares at $50.00 each, expecting total gross proceeds of $60 million, indicating the company's ability to raise capital in the market.
- Pre-Funded Warrants: The company is also offering pre-funded warrants for 50,000 shares at $49.99 each to a specific investor, a strategy aimed at attracting investment and enhancing liquidity.
- Additional Share Option: Spruce Biosciences has granted underwriters a 30-day option to purchase up to 180,000 additional shares, which could further increase the total financing and meet market demand.
- Stock Price Reaction: Following the public offering announcement, Spruce Biosciences' stock price fell 13.44% in after-hours trading to $60.50, reflecting market caution regarding the offering.
See More
Spruce Biosciences Prices Public Offering at $50 per Share
- Offering Size: Spruce Biosciences announced a public offering of 1,150,000 shares at $50.00 per share, expecting gross proceeds of $60 million, reflecting the company's strong fundraising capability and market confidence in the biopharmaceutical sector.
- Pre-Funded Warrant Arrangement: The offering includes pre-funded warrants for 50,000 shares at a purchase price of $49.99 per share for a specific investor, indicating the company's flexible financing strategy to attract investment.
- Underwriter Lineup: The offering is managed by Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. as joint book-running managers, showcasing the company's strong backing and professionalism in capital markets.
- Registration Statement Validity: The offering is conducted under a shelf registration statement on Form S-3 filed on October 29, 2025, and declared effective by the SEC on November 26, 2025, ensuring compliance and transparency in the fundraising process.
See More
Spruce Biosciences Prices Public Offering at $50 per Share
- Offering Size: Spruce Biosciences announced a public offering of 1,150,000 shares at $50.00 per share, expecting gross proceeds of $60 million, indicating strong fundraising capability in the biopharmaceutical sector.
- Pre-Funded Warrant Arrangement: The offering includes pre-funded warrants for 50,000 shares at a purchase price of $49.99 per share for a specific investor, reflecting the company's flexible financing strategy to meet investor demand.
- Underwriter Team: The offering is managed by Leerink Partners, Guggenheim Securities, and Oppenheimer & Co., demonstrating market confidence and support for Spruce Biosciences.
- Registration Statement Validity: The offering is based on a shelf registration statement filed on October 29, 2025, indicating the company's commitment to compliance and transparency, which helps enhance investor trust.
See More
SPRUCE BIOSCIENCES, INC ANNOUNCES PUBLIC OFFERING OF 1,150,000 SHARES PRICED AT $50.00 EACH
Company Announcement: Spruce Biosciences, Inc. has announced a public offering of 1,150,000 shares.
Share Price: The shares are being offered at a price of $50.00 per share.
See More
SPRUCE BIOSCIENCES REVEALS PRICING FOR PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS
Public Offering Announcement: Spruce Biosciences has announced the pricing of its public offering of common stock.
Pre-Funded Warrants: The offering also includes pre-funded warrants, allowing investors to purchase shares at a reduced price.
See More
Spruce Biosciences Launches Public Offering
- Public Offering Initiation: Spruce Biosciences announced late Monday that it has commenced an underwritten public offering, although the specific amount to be raised has not been disclosed, indicating the company's intent to enhance financial flexibility through capital markets.
- Market Reaction Anticipation: This offering may attract investor interest, particularly in the biotech sector, as the potential use of funds could include research and development and market expansion, thereby enhancing the company's long-term growth prospects.
- Strategic Financing Plan: The implementation of the public offering will provide the necessary funding support for the company to advance its product development and clinical trials, especially in the currently competitive biopharmaceutical market.
- Investor Confidence Challenge: While market reactions to biotech offerings can vary, Spruce Biosciences' action may influence its stock performance, prompting investors to monitor subsequent market feedback and the company's financial health.
See More
